259793-96-9 in stock High quality favipiravir

favipiravir, a new broad-spectrum antiviral drug developed by Toyama Chemical Pharmaceuticals of Japan to target RNA-dependent RNA polymerase (RdRp), was approved in Japan in March 2014 for the treatment of new and compound hairdressing influenza.

Fapiravi is a nucleoside antiviral drug, and the mechanism of action has not been fully explained. Its target is RNA polymerase, which is dependent on viral RNA. The drug is absorbed orally and converted into a nucleoside triphosphate with bioactive Fapiravi, with a similar structure to radon, which can compete with niobium for viral RNA polymerase; Fapiravi's nucleoside triphosphate can also be inserted into the viral RNA chain, triggering the virus's deadly mutation. Therefore, from a mechanism, fapiravi has potential antiviral effects on all kinds of RNA viruses.

Our advantages:
1) High quality, reasonable price and excellent service.
2) We have our own chemical sub-package warehouse, can do ciq and supply hazardous cargo packing license.
3) Company located in shandong province, which is famous for its chemical industry in china. and for most chemical products we can found producers here.
4) Nearby the world-famous seaport-qingdao. thereby we have smooth transportation ways for our worldwide clients.

why choose us:

factory and warehouse

quick delivery

import and export

saving mouey and time